LV12291B - COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES - Google Patents
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES Download PDFInfo
- Publication number
- LV12291B LV12291B LVP-99-27A LV990027A LV12291B LV 12291 B LV12291 B LV 12291B LV 990027 A LV990027 A LV 990027A LV 12291 B LV12291 B LV 12291B
- Authority
- LV
- Latvia
- Prior art keywords
- compound
- alkylene
- hetero
- formula
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-00-31A LV12459B (en) | 1996-07-30 | 2000-02-25 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |
| LVP-00-30A LV12458B (en) | 1996-07-30 | 2000-02-25 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2313996P | 1996-07-30 | 1996-07-30 | |
| US89577297A | 1997-07-17 | 1997-07-17 | |
| PCT/US1997/013422 WO1998004537A1 (en) | 1996-07-30 | 1997-07-30 | Novel compounds and compositions for treating diseases associated with tryptase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12291A LV12291A (lv) | 1999-06-20 |
| LV12291B true LV12291B (en) | 2000-04-20 |
Family
ID=26696778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-99-27A LV12291B (en) | 1996-07-30 | 1999-02-18 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934293A1 (sv) |
| JP (1) | JP2001509787A (sv) |
| KR (1) | KR20000029679A (sv) |
| CN (1) | CN1073103C (sv) |
| AU (1) | AU733621B2 (sv) |
| CA (1) | CA2262542A1 (sv) |
| CZ (1) | CZ29799A3 (sv) |
| EE (1) | EE9900036A (sv) |
| FI (1) | FI990171A (sv) |
| HU (1) | HUP0003267A3 (sv) |
| LV (1) | LV12291B (sv) |
| NO (1) | NO990433L (sv) |
| NZ (1) | NZ333713A (sv) |
| PL (1) | PL331465A1 (sv) |
| SI (1) | SI9720047A (sv) |
| SK (1) | SK8599A3 (sv) |
| WO (1) | WO1998004537A1 (sv) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| ATE282607T1 (de) * | 1998-02-06 | 2004-12-15 | Max Planck Gesellschaft | Tryptase-inhibitoren |
| JP2002502845A (ja) * | 1998-02-06 | 2002-01-29 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | トリプターゼ阻害物質 |
| WO2000014097A2 (de) * | 1998-09-04 | 2000-03-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyranosen |
| SI1208089T1 (en) | 1999-08-10 | 2005-04-30 | Altana Pharma Ag | Diazocin-dione derivatives and their use as tryptase inhibitors |
| WO2001019809A1 (en) * | 1999-09-14 | 2001-03-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| AU1413301A (en) * | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| DE19955476A1 (de) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| CA2392127A1 (en) | 1999-12-20 | 2001-06-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| CA2392121A1 (en) * | 1999-12-20 | 2001-06-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| DK1358182T3 (da) * | 2001-01-31 | 2004-12-20 | Altana Pharma Ag | Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer |
| EP1368317B1 (en) | 2001-02-21 | 2006-12-27 | Altana Pharma AG | Tryptase inhibitors |
| ES2287268T3 (es) | 2001-02-21 | 2007-12-16 | Nycomed Gmbh | Inhibidores de triptasa. |
| JP2004525926A (ja) * | 2001-03-15 | 2004-08-26 | アルタナ ファルマ アクチエンゲゼルシャフト | トリプターゼ阻害剤 |
| WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
| EP1404324B2 (en) | 2001-06-11 | 2011-04-06 | XenoPort, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| WO2002102771A1 (en) | 2001-06-19 | 2002-12-27 | Altana Pharma Ag | Tryptase inhibitors |
| BRPI0517227B8 (pt) | 2004-11-04 | 2021-05-25 | Xenoport Inc | comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido |
| TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| US8399519B2 (en) * | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
| FR3038605B1 (fr) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation |
| US20200199168A1 (en) * | 2017-05-12 | 2020-06-25 | Riken | Class a gpcr-binding compound modifier |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
| AU683459B2 (en) * | 1993-03-12 | 1997-11-13 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| WO1995032945A1 (en) * | 1994-06-01 | 1995-12-07 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
| WO1996009297A1 (en) * | 1994-09-23 | 1996-03-28 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell inflammatory condition |
| CA2216151A1 (en) * | 1995-03-24 | 1996-10-03 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/hu unknown
- 1997-07-30 NZ NZ333713A patent/NZ333713A/xx unknown
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Application Discontinuation
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
- 1997-07-30 PL PL97331465A patent/PL331465A1/xx unknown
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/ko not_active Application Discontinuation
- 1997-07-30 JP JP50913698A patent/JP2001509787A/ja active Pending
- 1997-07-30 SI SI9720047A patent/SI9720047A/sl unknown
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/cs unknown
- 1997-07-30 CN CN97196877A patent/CN1073103C/zh not_active Expired - Fee Related
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 SK SK85-99A patent/SK8599A3/sk unknown
- 1997-07-30 EE EEP199900036A patent/EE9900036A/xx unknown
-
1999
- 1999-01-29 NO NO990433A patent/NO990433L/no not_active Application Discontinuation
- 1999-01-29 FI FI990171A patent/FI990171A/sv unknown
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU733621B2 (en) | 2001-05-17 |
| HUP0003267A3 (en) | 2002-02-28 |
| CN1226892A (zh) | 1999-08-25 |
| JP2001509787A (ja) | 2001-07-24 |
| NO990433D0 (no) | 1999-01-29 |
| LV12291A (lv) | 1999-06-20 |
| EP0934293A1 (en) | 1999-08-11 |
| CZ29799A3 (cs) | 1999-06-16 |
| CN1073103C (zh) | 2001-10-17 |
| AU3967097A (en) | 1998-02-20 |
| SI9720047A (sl) | 1999-08-31 |
| FI990171A (sv) | 1999-03-23 |
| KR20000029679A (ko) | 2000-05-25 |
| WO1998004537A1 (en) | 1998-02-05 |
| NO990433L (no) | 1999-03-25 |
| PL331465A1 (en) | 1999-07-19 |
| FI990171A0 (sv) | 1999-01-29 |
| CA2262542A1 (en) | 1998-02-05 |
| EE9900036A (et) | 1999-08-16 |
| HUP0003267A2 (hu) | 2001-06-28 |
| NZ333713A (en) | 2000-12-22 |
| SK8599A3 (en) | 2000-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV12291B (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES | |
| AU686115B2 (en) | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation | |
| SU1581221A3 (ru) | Способ получени (4-пиперидинилметил- или гетеро)-пуринов или их фармацевтически приемлемых солей с кислотами, или стереоизомеров | |
| US5607936A (en) | Substituted aryl piperazines as neurokinin antagonists | |
| US7932247B2 (en) | M3 muscarinic acetylcholine receptor antagonists | |
| US20090142279A1 (en) | Novel m3 muscarinic acetylcholine receptor antagonists | |
| CZ87097A3 (en) | Preparation for therapy and therapeutical methods for treating inflammations mediated by mast cells | |
| WO2000027826A1 (de) | Neue pyrimidine, deren herstellung und verwendung | |
| US5574042A (en) | Imidazo [1,2-a] pyridines and their pharmaceutical use | |
| CZ20012562A3 (cs) | Amidové sloučeniny | |
| US6489327B1 (en) | Tryptase inhibitors | |
| DE4243858A1 (de) | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
| EP1057815B1 (en) | Cyclic amide compounds | |
| JP2003509417A (ja) | トリプターゼインヒビター | |
| AU5625499A (en) | Novel pyranoses | |
| ES2222259T3 (es) | Inhibidores de triptasa. | |
| NZ506614A (en) | Compounds for treating diseases associated with tryptase activity | |
| JPH07330777A (ja) | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 | |
| MXPA99001105A (en) | Novel compounds and compositions for treating diseases associated with tryptase activity | |
| Kaur et al. | Synthesis and antispasmodic activity evaluation of bis-(papaverine) analogues | |
| EP1368317B1 (en) | Tryptase inhibitors | |
| LT4587B (lt) | Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu | |
| LV12459B (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES | |
| DE1445677C (de) | Acylaminopyndine | |
| MXPA00008146A (en) | Cyclic amide compounds |